Ionis and Biogen Announce Topline Phase 1/2 Study Results of Investigational Drug in Amyotrophic Lateral Sclerosis

/PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) and Biogen Inc. (Nasdaq: BIIB) announced the decision to terminate development of BIIB105 (ION541)...

Related Keywords

Cambridge ,Cambridgeshire ,United Kingdom ,Sweden ,Stockholm ,Stephanie Fradette ,Frank Bennett ,Youtube ,Ionis Pharmaceuticals Inc ,Biogen Inc ,Nasdaq ,Astrazeneca ,Exchange Commission ,European Network To Cure ,Linkedin ,Facebook ,Ionis Pharmaceuticals ,Neuromuscular Development Unit ,European Network ,Continuous Commitment ,